AGENT DELIVERY SYSTEM AND USES OF SAME

• US 20090143761A1
• Filed: 12/03/2007
• Published: 06/04/2009
• Est. Priority Date: 06/03/2005
• Status: Abandoned Application

• Current Assignee: Transdermal Patents Company LLC
• Original Assignee: Transdermal Patents Company LLC
• Inventors: Swartz, Kenneth H., Hower, Robert, Cantor, Scott A., Cantor, Hal C.
• Application Number:
  US11/949,718
• Publication Number:
  US 20090143761A1
• Time in Patent Office: Days
• US Class Current: 604/501
• CPC Class Codes: A61N 1/0412 Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/0444 Membrane
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation

Abstract

The use of an automated, controllable, and affixable pulsatile for treating diseases, having an automated controller for controlling the delivery of drug to a patient, an agent delivery reservoir containing an agent operatively connected to the automated controller, a reservoir controller operatively connected to the automated controller and the reservoir for controlling the delivery of agent to a patient, and a feedback control operatively connected to the automated controller for providing feedback with regard to the drug requirements of the patient for use in treating diseases.

Claims

1. A method for delivering an agent to a patient from an agent delivery device, the agent delivery device including:

an agent delivery reservoir containing an agent to be administered to a patient;

an electrolyte that is mixed with the agent and contained in the reservoir and traps the agent until electric current is applied;

an agent delivery surface in communication with the electrolyte-agent mixture, the agent delivery surface adapted to contact the patient and deliver agent received from the reservoir to the patient; and

a controller in communication with the electrolyte-agent mixture, the controller providing a series of control pulses to the electrolyte-agent mixture, each pulse allowing the delivery system to administer a portion of the agent to the patient, the series of pulses providing a temporally varying concentration of agent in the patient,

the method comprising;

contacting the patient with the agent delivery surface; and

operating the controller to administer the agent to the patent.

2. The method of claim 1, wherein the electrolyte comprises an iontophoretic electrically conductive material.

3. The method of claim 1, wherein the agent comprises:

an anti-malarial agent.

4. The method of claim 1, wherein the agent comprises an antimalarial drug.

5. The method of claim 4, wherein the antimalarial drug is selected from the group consisting of amodiaquine, artemether, artemisinin, artesunate, atovaquone, cinchonine, cinchonidine, chloroquine, doxycycline, halofantrine, mefloquine, primaquine, pyrimethamine, quinine, quinidine, sulfadoxine, and combinations thereof.

6. The method of claim 1, wherein the agent comprises a hormone.

7. The method of claim 6 wherein the hormone is selected from the group consisting of gonadotropin releasing hormones (GnRH), estradiol, progesterone, growth hormone, thyroid stimulating hormone (TSH) prolactin, human parathyroid hormone buserelin, insulin, and combinations thereof.

8. The method of claim 1, wherein the agent comprises an antiretroviral drug.

9. The method of claim 8 wherein the antiretroviral drug is selected from the group consisting of abacavir, didanosine, indinavir, lamivudine, nevirapine, ritonavir, saquinavir mesylate, zalcitabine, zidovudine, and combinations thereof.

10. The method of claim 1, wherein the agent comprises an antibiotic drug.

11. The method of claim 1 wherein the antibiotic drug is selected from the group consisting of ampicillin, azithromycin, doxycycline, erythromycin, penicillin, tetracycline, and combinations thereof.

12. The method of claim 1, wherein the agent comprises an antipsychotic drug.

13. The method of claim 1, wherein the agent comprises an addictive agent.

14. The method of claim 13 wherein the addictive agent is selected from the group consisting of nicotine, morphine, methadone, oxycontin, cocaine, barbiturates and combinations thereof.

15. The method of claim 1, wherein the agent comprises a chemotherapeutic cancer agent.

16. The method of claim 15 wherein the chemotherapeutic cancer agent is selected from the group consisting of Buserelin, Taxol, and combinations thereof.

17. The method of claim 1 wherein the agent comprises a cosmetic anti-wrinkle agent.

18. The method of claim 17, wherein the cosmetic anti-wrinkle agent is selected from the group consisting of acollagen, collagen-glycosaminoglycan, polytetrafluoroethylene, poly-L-lactide and poly(ethyleneoxide)-poly(butyleneterephthalate), polyglactin, polyglycolic acid, biosynthetic materials, hydrocolloid-like materials, and combinations thereof.

19. The method of claim 1, wherein the agent comprises a naturally occurring or synthetic hydrophilic or hydrophobic agent.

20. The method of claim 1, wherein the agent comprises an analgesic.

21. The method of claim 20, wherein the analgesic agent is selected from the group consisting of non-steroidal anti-inflammatory drugs, steroids, COX-1 inhibitors, COX-2 inhibitors, and combinations thereof.